TrialInvestigational new drugs2013
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Nigel Bundred et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
47 papers cite it
this papertrialcites it